Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment

Nature Reviews Endocrinology

Volumn 10, Issue 5, 2014, Pages 276-281

  Fonseca, Vivian A ^a   Haggar, Michelle A ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

COMORBIDITY; HEALTH CARE SYSTEM; HUMAN; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GOALS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; INSULIN; MIDDLE AGED; PREGNANCY;

EID: 84899481504     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.17     Document Type: Review

References (63)

1. Fonseca, V. A., Pendergrass, M. & Harrison McDuffie, R. Diabetes in Clinical Practice (Springer, 2009).
2. Fonseca, V. A. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32 (Suppl. 2), S151-S156 (2009).
3. Unger, R. H. & Grundy, S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 28, 119-121 (1985). (Pubitemid 15102179)
4. Kahn, S. E., McCulloch, D. K. & Porte, D. in International Textbook of Diabetes Mellitus 2nd edn (eds Alberti, K. G. M. M., Zimmet, P., Defronzo, R. A.) 337-354 (John Wiley & Sons, 1997).
5. Action to Control Cardiovascular Risk in Diabetes Study Group et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
6. ADVANCE Collaborative Group et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008).
7. Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129-139 (2009).
8. Kelly, T. N. et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann. Intern. Med. 151, 394-403 (2009).
9. Desouza, C. V., Bolli, G. B. & Fonseca, V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33, 1389-1394 (2010).
10. [No authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853 (1998).
11. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 37 (Suppl. 1), S14-S80 (2014).
12. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diabetes 32 (Suppl. 1), S1-S201 (2008).
13. Rydén, L. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 28, 88-136 (2007). (Pubitemid 46137814)
14. Handelsman, Y. et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr. Pract. 17 (Suppl. 2), 1-53 (2011).
15. Bhattacharyya, O. K., Estey, E. A. & Cheng, A. Y. Canadian Diabetes Association. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can. Fam. Physician 55, 39-43 (2009).
16. Inzucchi, S. E. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35, 1364-1379 (2012).
17. Phillips, L. S. et al. Clinical inertia. Ann. Intern. Med. 135, 825-834 (2001).
18. Aljabri, K., Kozak, S. & Thompson, D. M. Addition of pioglitazone or bedtime insulin to maximal doses of sulphonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am. J. Med. 116, 230-235 (2004). (Pubitemid 38224230)
19. Rosenstock, J. et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29, 554-559 (2006). (Pubitemid 44115353)
20. DeFronzo, R. A., Stonehouse, A. H., Han, J. & Wintle, M. E. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-Analysis of randomized clinical trials. Diabet. Med. 27, 309-317 (2010).
21. Holman, R. R. et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N. Engl. J. Med. 361, 1736-1747 (2009).
22. Holman, R. R. et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N. Engl. J. Med. 357, 1716-1730 (2007). (Pubitemid 350005153)
23. Meneghini, L., Mersebach, H., Kumar, S., Svendsen, A. L. & Hermansen, K. Comparison of 2 intensification regimens with rapid-Acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr. Pract. 17, 727-736 (2011).
24. Buse, J. B. et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 32, 1007-1013 (2009).
25. Riddle, M. C. et al. Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: twice-daily aspart premixed vs glargine [abstract]. Diabetologia 54 (Suppl. 1), A1036 (2011).
26. Davidson, M. B., Raskin, P., Tanenberg, R. J., Vlajnic, A. & Hollander, P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr. Pract. 17, 395-403 (2011).
27. Riddle, M. C., Rosenstock, J. & Gerich, J., Insulin Glargine 4002 Study Investigators. The treat-To-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26, 3080-3086 (2003). (Pubitemid 37339502)
28. Raskin, P. et al. The INITIATE Study Group: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28, 260-265 (2005). (Pubitemid 40170923)
29. Hermansen, K. et al. A 26-week, randomized, parallel, treat-To-Target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29, 1269-1274 (2006). (Pubitemid 44125921)
30. Riddle, M. C. The Treat-To-Target Trial and related studies. Endocr. Pract. 12 (Suppl. 1), 71-79 (2006). (Pubitemid 44963617)
31. Rosenstock, J. et al. A randomised, 52-week, treat-To-Target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51, 408-416 (2008).
32. Ligthelm, R. F. et al. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study. Endocr. Pract. 17, 41-50 (2011).
33. Swinnen, S. G., Simon, A. C., Holleman, F., Hoekstra, J. B. & Devries, J. H. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD006383. http://dx.doi.org/10.1002/14651858.CD006383.pub2.
34. Rosenstock, J. et al. Reduced hypoglycemia risk with insulin glargine: a meta-Analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28, 950-955 (2005). (Pubitemid 40434505)
35. Nathan, D. et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 1963-1972 (2006). (Pubitemid 44156663)
36. Davies, M. et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28, 1282-1288 (2005). (Pubitemid 40756686)
37. Meneghini, L., Koenen, C., Weng, W. & Selam, J. L. The usage of a simplified self-Titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes-results of the randomized, controlled PREDICTIVE 303 study. Diabetes Obes. Metab. 9, 902-913 (2007). (Pubitemid 47555212)
38. Davies, M., Lavalle-González, F., Storms, F., Gomis, R. & AT.LANTUS Study Group. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes. Metab. 10, 387-399 (2008). (Pubitemid 351524286)
39. Origin Trial Investigators et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am. Heart J. 155, 26-32 (2008).
40. Aschner, P. et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet 379, 2262-2269 (2012).
41. Buse, J. B. et al. Use of twice-daily exenatide in basal insulin-Treated patients with type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154, 103-112 (2011).
42. Riddle, M. C. et al. Efficacy and safety of once-daily lixisenatide in type 2 diabetes insufficiently controlled with basal insulin metformin: GetGoal-L Study [abstract]. Diabetes 61 (Suppl. 1), A251 (2012).
43. Fonseca, V. et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50, 1148-1155 (2007). (Pubitemid 46701545)
44. Fonseca, V., Baron, M., Shao, Q. & Dejager, S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm. Metab. Res. 40, 427-430 (2008). (Pubitemid 351967136)
45. Davidson, M. B. Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care 28, 222-224 (2005). (Pubitemid 40095806)
46. Alberti, G. The DAWN (Diabetes Attitudes, Wishes, and Needs) study. Pract. Diabetes Int. 19, 22-24 (2002).
47. Stetson, B. et al. Embracing the evidence on problem solving in diabetes self-management education and support. SelfCare 1, 83-99 (2010).
48. Meece, J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 32, 9S-18S (2006). (Pubitemid 43206838)
49. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 36, S11-S66 (2013).
50. Minze, M., Dalal, K. & Irons, B. K. Removing barriers to insulin use. J. Fam. Pract. 60, 577-580 (2011).
51. Peyrot, M. et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs study. Diabetes Care 28, 2673-2679 (2005). (Pubitemid 43951158)
52. American Association of Diabetes Educators. Strategies for insulin injection therapy in diabetes self-management. AADE White Papers [online], http://www.diabeteseducator.org/export/sites/aade/-resources/pdf/research/ AADE-MedEd.pdf (2011).
53. Perfetti, R. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol. Ther. 12 (Suppl. 1), S79-S85 (2010).
54. Funnell, M. M. Overcoming barriers to the initiation of insulin therapy. Clin. Diabetes. 25, 36-38 (2007).
55. Rodbard, H. W. et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 15, 540-559 (2009).
56. Shafiee, G., Mohajeri-Tehrani, M., Pajouhi, M. & Larijani, B. The importance of hypoglycemia in diabetic patients. J. Diabetes Metab. Disord. 11, 17 (2012).
57. [No authors listed] Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care 23, 381-389 (2000).
58. Fagot-Campagna, A. Emergence of type 2 diabetes mellitus in children: epidemiological evidence. J. Pediatr. Endocrinol. Metab. 13 (Suppl. 6), 1395-1402 (2000). (Pubitemid 32061572)
59. Patton, S. R., Eder, S., Schwab, J. & Sisson,C. M. Survey of insulin site rotation in youth with type 1 diabetes mellitus. J. Pediatr. Health Care 24, 365-371 (2010).
60. Mannucci, E., Cremasco, F., Romoli, E. & Rossi, A. The use of insulin in elderly patients with type 2 diabetes mellitus. Expert Opin. Pharmacother. 12, 2865-2881 (2011).
61. Berlie, H. D. & Garwood, C. L. Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. Ann. Pharmacother. 44, 712-717 (2010).
62. Moen, M. F. et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1121-1127 (2009).
63. Rabkin, R., Simon, N. M., Steiner, S. & Colwell, J. A. Effect of renal disease on renal uptake and excretion of insulin in man. N. Engl. J. Med. 282, 182-187 (1970).